tiprankstipranks
AbCellera down 7% after FDA announces bebtelovimab not authorized in U.S.
The Fly

AbCellera down 7% after FDA announces bebtelovimab not authorized in U.S.

Shares of AbCellera (ABCL) are down 87c, or 7%, to $12.49 after the FDA announced that bebtelovimab is not currently authorized for emergency use in the U.S. because it is not expected to neutralize Omicron subvariants BQ.1 and BQ.1.1. Eli Lilly (LLY) and its authorized distributors have paused commercial distribution of bebtelovimab until further notice by the Agency, the FDA stated.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on ABCL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles